



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 5, 2009

To: N083E Investigators, CRAs, and Study Teams

From: Lynn M Flickinger
NCCTG Project Manager

Re: N083E, Phase II Safety Study of Docetaxel and Carboplatin in Combination with Trastuzumab and Lapatinib in Early Breast Cancer

Safety Teleconferences for Investigators who enter patients in the Safety Cohort

Per protocol, the investigators who enter patients into the Safety Cohort must participate in twice-monthly teleconferences to discuss adverse events and issues related to patient safety. These calls are to facilitate rapid sharing of information regarding patient safety for this drug combination.

Teleconferences are scheduled on **2nd and 4th Thursdays** of each month from **2-3pm Central Time** (3-4pm Eastern Time). The following information should be used to participate in the call:

Call Global Crossing at 1-866-365-4406 and enter Participant Code: 2844481

If you have any questions about the information in this memo, please email Lynn Flickinger at flickinger.lynn@mayo.edu or Kristen Perkins at perkins.kristen@mayo.edu.